Optimization and validation of a UPLC-MS/MS assay for simultaneous quantification of 2,8-dihydroxyadenine, adenine, allopurinol, oxypurinol and febuxostat in human plasma

J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Mar 1:1235:124041. doi: 10.1016/j.jchromb.2024.124041. Epub 2024 Feb 5.

Abstract

Adenine phosphoribosyltransferase (APRT) deficiency is a rare , hereditary disorder characterized by renal excretion of 2,8-dihydroxyadenine (DHA), leading to kidney stone formation and chronic kidney disease (CKD). Treatment with a xanthine oxidoreductase inhibitor, allopurinol or febuxostat, reduces urinary DHA excretion and slows the progression of CKD. The method currently used for therapeutic monitoring of APRT deficiency lacks specificity and thus, a more reliable measurement technique is needed. In this study, an ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of DHA, adenine, allopurinol, oxypurinol and febuxostat in human plasma was optimized and validated. Plasma samples were prepared with protein precipitation using acetonitrile followed by evaporation. The chemometric approach design of experiments was implemented to optimize gradient steepness, amount of organic solvent, flow rate, column temperature, cone voltage, desolvation temperature and desolvation flow rate. Experimental screening was conducted using fractional factorial design with addition of complementary experiments at the axial points for optimization of peak area, peak resolution and peak width. The assay was validated according to the US Food and Drug Administration guidelines for bioanalytical method validation over the concentration range of 50 to 5000 ng/mL for DHA, allopurinol and febuxostat, 100 to 5000 ng/mL for adenine and 50 to 12,000 ng/mL for oxypurinol, with r2 ≥ 0.99. The analytical assay achieved acceptable performance of accuracy (-10.8 to 8.3 %) and precision (CV < 15 %). DHA, adenine, allopurinol, oxypurinol and febuxostat were stable in plasma samples after five freeze-thaw cycles at -80 °C and after storage at -80 °C for 12 months. The assay was evaluated for quantification of the five analytes in clinical plasma samples from six APRT deficiency patients and proved to be both efficient and accurate. The proposed assay will be valuable for guiding pharmacotherapy and thereby contribute to improved and more personalized care for patients with APRT deficiency.

Keywords: Adenine phosphoribosyltransferase (APRT) deficiency; Clinical mass spectrometry; Design of experiments (DoE); Diagnosis; Pharmacotherapy monitoring; Rare kidney stone diseases; Validation.

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / metabolism
  • Adenine Phosphoribosyltransferase / deficiency*
  • Adenine Phosphoribosyltransferase / metabolism
  • Allopurinol* / therapeutic use
  • Chromatography, Liquid
  • Febuxostat
  • Humans
  • Liquid Chromatography-Mass Spectrometry
  • Metabolism, Inborn Errors*
  • Oxypurinol
  • Renal Insufficiency, Chronic* / drug therapy
  • Tandem Mass Spectrometry / methods
  • Urolithiasis*

Substances

  • Allopurinol
  • Oxypurinol
  • Febuxostat
  • 2,8-dihydroxyadenine
  • Adenine
  • Adenine Phosphoribosyltransferase

Supplementary concepts

  • Adenine phosphoribosyltransferase deficiency